A clinical trial comparing Armour Thyroid (NDT) and Levothyroxine (LT4) is now recruiting patients in the United States. The sponsor of the study is Allergan, the makers of Armour Thyroid in the United States. They hope to recruit 220 patients at multiple locations listed on the clinical trial website. In this post, I provide what … Continue reading New clinical trial of Armour Thyroid is recruiting U.S. patients
I'd like to talk about contemporary researchers' rigid and limited approach to combination therapy. This is the model whose many limitations I point out with the ridiculously long label "mini-T3-mono-combination" therapy. I'll go over some of the history behind this model, the source of the rigid ratios that we learned about in our series on … Continue reading The mini-T3-mono-combination therapy model vs NDT and others
Most studies of Low T3 syndrome (NTIS) routinely EXCLUDE thyroid patients. Sadly, our exclusion has become a research tradition. In this post, I lay out the landscape and extent of our exclusion from this valuable area of thyroid hormone health research. Everyone loses by our exclusion. Especially thyroid patients. Everyone has something to gain from … Continue reading Thyroid patients are routinely excluded from low T3 syndrome (NTIS) research
Clinical trials of T3 (Liothyronine) have been barking up the wrong tree. The limitations of their research designs are now actively harming patients who need T3 medication. Prices for T3 have been rising, medical prejudice against T3 is rising, worldwide T3 shortages are occurring, and patients who truly require T3 are being harmed by denying … Continue reading Study the patients who need T3 and are harmed by its withdrawal
Why have clinical trials of T3-T4 combination therapy failed to show significant benefit? Hoermann et al explain that the trials and the meta-analyses exhibit a fundamental problem with research methodology and a fundamental misunderstanding of thyroid hormone relationships that results in statistical errors. SOURCE Hoermann, R., Midgley, J. E. M., Larisch, R., & Dietrich, J. … Continue reading Simpson’s paradox: Hoermann et al explain why T4-T3 therapy trials are faulty
